The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2015 | Novel agents for MDS on the basis of understanding disease biology
Valeria Santini
• 12 Jun 2015
Myelodysplastic syndromes (MDS) represent a clinically heterogeneous group of disorders with challenging unmet therapeutic needs. At the 20th Congress of the European Hematology Association (EHA), Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses emerging agents for the treatment of patients with MDS, including transforming growth factor-beta inhibitors, thrombopoietic agents and targets of mutant IDH2.
